Telomerase: a key player in the pathogenesis of non-alcoholic fatty liver disease?

References

• Zheng KI, Fan JG, Shi JP, et al. From NAFLD to MAFLD: a “redefining” moment for fatty liver disease. Chin Med J (Engl). 2020;133(19):2271-2273.
   PubMed Web of Science ®Google Scholar
• Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol. 2019 Jun;16(6):377–386.
   Google Scholar
• Stefan N, Häring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019 Apr;7(4):313–324.
   PubMed Web of Science ®Google Scholar
• Eslam M, George J. Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. Nat Clin Pract Gastroenterol Hepatol. 2020 Jan;17(1):40–52.
   Google Scholar
• Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol. 2018 Feb;68(2):268–279.
   PubMed Web of Science ®Google Scholar
• Patnaik MM, Kamath PS, Simonetto DA. Hepatic manifestations of telomere biology disorders. J Hepatol. 2018 Sep;69(3):736–743.
   PubMed Web of Science ®Google Scholar
• Sheka AC, Adeyi O, Thompson J, et al. Nonalcoholic Steatohepatitis: a Review. Jama. 2020 Mar 24;323(12):1175–1183.
   PubMed Web of Science ®Google Scholar
• Anstee QM, Reeves HL, Kotsiliti E, et al. From NASH to HCC: current concepts and future challenges. Nat Clin Pract Gastroenterol Hepatol. 2019 Jul;16(7):411–428.
   Google Scholar
• Aubert G, Lansdorp PM. Telomeres and aging. Physiol Rev. 2008 Apr;88(2):557–579.
   PubMed Web of Science ®Google Scholar
• Podlevsky JD, Chen JJ. Evolutionary perspectives of telomerase RNA structure and function. RNA Biol. 2016Aug2;13(8):720–732.
   PubMed Web of Science ®Google Scholar
• Shay JW. Role of telomeres and telomerase in aging and cancer. Cancer Discov. 2016 Jun 6;6(6):584–593.
   PubMed Web of Science ®Google Scholar
• Blackburn EH. Structure and function of telomeres. Nature. 1991 Apr 18;350(6319):569–573.
   PubMed Web of Science ®Google Scholar
• Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res. 1961 Dec;25(3):585–621.
   PubMed Web of Science ®Google Scholar
• Donati B, Valenti VL. Telomeres, NAFLD and chronic liver disease. Int J Mol Sci. 2016 Mar 15;17(3):383.
   PubMed Web of Science ®Google Scholar
• Chan H, Wang Y, Feigon J. Progress in human and tetrahymena telomerase structure determination. Annu Rev Biophys. 2017 May;46(1):199–225.
   PubMedGoogle Scholar
• Nguyen THD, Tam J, Wu RA, et al. Cryo-EM structure of substrate-bound human telomerase holoenzyme. Nature. 2018 May;557(7704):190–195.
   PubMed Web of Science ®Google Scholar
• Reichow SL, Hamma T, Ferré-D’Amaré AR, et al. The structure and function of small nucleolar ribonucleoproteins. Nucleic Acids Res. 2007;35(5):1452–1464.
   PubMed Web of Science ®Google Scholar
• Wang C, Meier UT. Architecture and assembly of mammalian H/ACA small nucleolar and telomerase ribonucleoproteins. EMBO J. 2004 Apr 21;23(8):1857–1867.
   PubMed Web of Science ®Google Scholar
• De Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 2005 Sep 15;19(18):2100–2110.
   PubMed Web of Science ®Google Scholar
• Xin H, Liu D, Wan M, et al. TPP1 is a homologue of ciliate TEBP-beta and interacts with POT1 to recruit telomerase. Nature. 2007 Feb 1;445(7127):559–562.
   PubMed Web of Science ®Google Scholar
• Hoffman H, Rice C, Skordalakes E. Structural analysis reveals the deleterious effects of telomerase mutations in bone marrow failure syndromes. J Biol Chem. 2017 Mar 17;292(11):4593–4601.
   PubMed Web of Science ®Google Scholar
• Zoller H, Tilg H. Nonalcoholic fatty liver disease and hepatocellular carcinoma. Metabolism. 2016 Aug;65(8):1151–1160.
   PubMed Web of Science ®Google Scholar
• Dokal I. Dyskeratosis congenita. A disease of premature ageing; 2001 Dec 358; Lancet (London, England): Suppl, S27.
   Google Scholar
• Calado RT, Young NS. Telomere diseases. N Engl J Med. 2009 Dec 10;361(24):2353–2365.
   PubMed Web of Science ®Google Scholar
• Chiba K, Johnson JZ, Vogan JM, et al. Cancer-associated TERT promoter mutations abrogate telomerase silencing. eLife. 2015;21:4.
   Google Scholar
• Dongiovanni P, Valenti L. Genetics of nonalcoholic fatty liver disease. Metabolism. 2016 Aug;65(8):1026–1037.
   PubMed Web of Science ®Google Scholar
• Arias-Salgado EG, Galvez E, Planas-Cerezales L, et al. Genetic analyses of aplastic anemia and idiopathic pulmonary fibrosis patients with short telomeres, possible implication of DNA-repair genes. Orphanet J Rare Dis. 2019 Apr 17;14(1):82.
   PubMedGoogle Scholar
• Haendeler J, Dröse S, Büchner N, et al. Mitochondrial telomerase reverse transcriptase binds to and protects mitochondrial DNA and function from damage. Arterioscler Thromb Vasc Biol. 2009 Jun;29(6):929–935.
   PubMed Web of Science ®Google Scholar
• Baffy G, Zhang CY, Glickman JN, et al. Obesity-related fatty liver is unchanged in mice deficient for mitochondrial uncoupling protein 2. Hepatology. 2002 Apr;35(4):753–761.
   PubMed Web of Science ®Google Scholar
• Kempiński R, Neubauer K, Wieczorek S, et al. 13C-methacetin breath testing in patients with non-alcoholic fatty liver disease. Adv Clin Exp Med. 2016 Jan-Feb;25(1):77–81.
   PubMed Web of Science ®Google Scholar
• Da Silva MS, Segatto M, Pavani RS, et al. Consequences of acute oxidative stress in leishmania amazonensis: from telomere shortening to the selection of the fittest parasites. Biochimica Et Biophysica Acta (BBA) - Molecular Cell Research. 2017 Jan;1864(1):138–150.
   PubMed Web of Science ®Google Scholar
• Thompson CAH, Gu A, Yang SY, et al. Transient telomerase inhibition with imetelstat impacts DNA damage signals and cell-cycle kinetics. Mol Cancer Res. 2018 Aug;16(8):1215–1225.
   PubMed Web of Science ®Google Scholar
• Kapuria D, Ben-Yakov G, Ortolano R, et al. The spectrum of hepatic involvement in patients with telomere disease. Hepatology. 2019 Jun;69(6):2579–2585.
   PubMed Web of Science ®Google Scholar
• Ma LJ, Wang XY, Duan M, et al. Telomere length variation in tumor cells and cancer-associated fibroblasts: potential biomarker for hepatocellular carcinoma. J Pathol. 2017 Dec;243(4):407–417.
   PubMed Web of Science ®Google Scholar
• Cai Y, Kandula V, Kosuru R, et al. Decoding telomere protein Rap1: its telomeric and nontelomeric functions and potential implications in diabetic cardiomyopathy. Cell Cycle (Georgetown, Tex). 2017 Oct 2;16(19):1765–1773.
   PubMed Web of Science ®Google Scholar
• Sfeir A, Kabir S, Van Overbeek M, et al. Loss of Rap1 induces telomere recombination in the absence of NHEJ or a DNA damage signal. Science (New York, NY). 2010 Mar 26;327(5973):1657–1661.
   Google Scholar
• Valenti L, Dongiovanni P, Maggioni M, et al. Liver transplantation for hepatocellular carcinoma in a patient with a novel telomerase mutation and steatosis. J Hepatol. 2013 Feb;58(2):399–401.
   PubMed Web of Science ®Google Scholar
• Calado RT, Brudno J, Mehta P, et al. Constitutional telomerase mutations are genetic risk factors for cirrhosis. Hepatology. 2011 May;53(5):1600–1607.
   PubMed Web of Science ®Google Scholar
• Chaiteerakij R, Roberts LR. Telomerase mutation: a genetic risk factor for cirrhosis. Hepatology. 2011 May;53(5):1430–1432.
   PubMed Web of Science ®Google Scholar
• Rudolph KL, Chang S, Millard M, et al. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science (New York, NY). 2000 Feb 18;287(5456):1253–1258.
   Google Scholar
• Barnard A, Moch A, Saab S. Relationship between telomere maintenance and liver disease. Gut Liver. 2019 Jan 15;13(1):11–15.
   PubMed Web of Science ®Google Scholar
• Satyanarayana A, Wiemann SU, Buer J, et al. Telomere shortening impairs organ regeneration by inhibiting cell cycle re-entry of a subpopulation of cells. EMBO J. 2003 Aug 1;22(15):4003–4013.
   PubMed Web of Science ®Google Scholar
• Carulli L, Anzivino C. Telomere and telomerase in chronic liver disease and hepatocarcinoma. World J Gastroenterol. 2014 May 28;20(20):6287–6292.
   PubMed Web of Science ®Google Scholar
• Sasaki M, Ikeda H, Yamaguchi J, et al. Telomere shortening in the damaged small bile ducts in primary biliary cirrhosis reflects ongoing cellular senescence. Hepatology. 2008 Jul;48(1):186–195.
   PubMed Web of Science ®Google Scholar
• Gutierrez-Reyes G, Del Carmen Garcia De Leon M, Varela-Fascinetto G, et al. Cellular senescence in livers from children with end stage liver disease. PloS One. 2010 Apr 21;5(4):e10231.
   PubMed Web of Science ®Google Scholar
• Kim D, Li AA, Ahmed A. Leucocyte telomere shortening is associated with nonalcoholic fatty liver disease-related advanced fibrosis. Liver Int. 2018 Oct;38(10):1839–1848.
   PubMed Web of Science ®Google Scholar
• Oh BK, Jo Chae K, Park C, et al. Telomere shortening and telomerase reactivation in dysplastic nodules of human hepatocarcinogenesis. J Hepatol. 2003 Nov;39(5):786–792.
   PubMed Web of Science ®Google Scholar
• Ju Z, Rudolph KL. Telomeres and telomerase in cancer stem cells. Eur J Cancer. 2006 Jun;42(9):1197–1203.
   PubMed Web of Science ®Google Scholar
• Nault JC, Calderaro J, Di Tommaso L, et al. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology. 2014 Dec;60(6):1983–1992.
   PubMed Web of Science ®Google Scholar
• Hakin-Smith V, Jellinek DA, Levy D, et al. Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet. 2003 Mar 8;361(9360):836–838.
   PubMed Web of Science ®Google Scholar
• Urabe Y, Nouso K, Higashi T, et al. Telomere length in human liver diseases. Liver. 1996 Oct;16(5):293–297.
   PubMedGoogle Scholar
• Garcia CK, Wright WE, Shay JW. Human diseases of telomerase dysfunction: insights into tissue aging. Nucleic Acids Res. 2007;35(22):7406–7416.
   PubMed Web of Science ®Google Scholar
• Plentz RR, Schlegelberger B, Flemming P, et al. Telomere shortening correlates with increasing aneuploidy of chromosome 8 in human hepatocellular carcinoma. Hepatology. 2005 Sep;42(3):522–526.
   PubMed Web of Science ®Google Scholar
• Farazi PA, Glickman J, Jiang S, et al. Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma. Cancer Res. 2003 Aug 15;63(16):5021–5027.
   PubMed Web of Science ®Google Scholar
• Turati F, Edefonti V, Talamini R, et al. Family history of liver cancer and hepatocellular carcinoma. Hepatology. 2012 May;55(5):1416–1425.
   PubMed Web of Science ®Google Scholar
• Valenti LVC, Baselli GA. Genetics of nonalcoholic fatty liver disease: a 2018 update. Curr Pharm Des. 2018;24(38):4566–4573.
   PubMed Web of Science ®Google Scholar
• Di Filippo M, Moulin P, Roy P, et al. Homozygous MTTP and APOB mutations may lead to hepatic steatosis and fibrosis despite metabolic differences in congenital hypocholesterolemia. J Hepatol. 2014 Oct;61(4):891–902.
   PubMed Web of Science ®Google Scholar
• Nault JC, Zucman-Rossi J. TERT promoter mutations in primary liver tumors. Clin Res Hepatol Gastroenterol. 2016 Feb;40(1):9–14.
   PubMed Web of Science ®Google Scholar
• Hartmann D, Srivastava U, Thaler M, et al. Telomerase gene mutations are associated with cirrhosis formation. Hepatology. 2011 May;53(5):1608–1617.
   PubMed Web of Science ®Google Scholar
• Kitada T, Seki S, Kawakita N, et al. Telomere shortening in chronic liver diseases. Biochem Biophys Res Commun. 1995 Jun 6;211(1):33–39.
   PubMed Web of Science ®Google Scholar
• Patel PL, Suram A, Mirani N, et al. Derepression of hTERT gene expression promotes escape from oncogene-induced cellular senescence. Proceedings of the National Academy of Sciences of the United States of America. 2016 Aug 23; 113( 34):E5024–33.
   Google Scholar
• Donati B, Pietrelli A, Pingitore P, et al. Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. Cancer Med. 2017 Aug;6(8):1930–1940.
   PubMed Web of Science ®Google Scholar
• Lee JH. Analysis of The Cancer Genome Atlas data to determine the correlation between PROX1 and TERT in hepatocellular carcinoma. Int J Cancer. 2019 Apr 1;144(7):1752–1753.
   PubMed Web of Science ®Google Scholar
• Ki Kim S, Ueda Y, Hatano E, et al. TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma. Int J Cancer. 2016 Dec 1;139(11):2512–2518.
   PubMed Web of Science ®Google Scholar
• In Der Stroth L, Tharehalli U, Günes C, et al. Telomeres and telomerase in the development of liver cancer. Cancers (Basel). 2020 Jul 24;12(8):2048.
   PubMed Web of Science ®Google Scholar
• Totoki Y, Tatsuno K, Covington KR, et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet. 2014 Dec;46(12):1267–1273.
   PubMed Web of Science ®Google Scholar
• Nault JC, Mallet M, Pilati C, et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun. 2013;4(1):2218.
   PubMedGoogle Scholar
• Kim H, Yoo JE, Cho JY, et al. Telomere length, TERT and shelterin complex proteins in hepatocellular carcinomas expressing “stemness”-related markers. J Hepatol. 2013 Oct;59(4):746–752.
   PubMed Web of Science ®Google Scholar
• Tejera AM, Stagno d’Alcontres M, Thanasoula M, et al. TPP1 is required for TERT recruitment, telomere elongation during nuclear reprogramming, and normal skin development in mice. Dev Cell. 2010 May 18;18(5):775–789.
   PubMed Web of Science ®Google Scholar
• Gardner JP, Li S, Srinivasan SR, et al. Rise in insulin resistance is associated with escalated telomere attrition. Circulation. 2005 May 3;111(17):2171–2177.
   PubMed Web of Science ®Google Scholar
• Dong K, Zhang Y, Huang JJ, et al. Shorter leucocyte telomere length as a potential biomarker for nonalcoholic fatty liver disease-related advanced fibrosis in T2DM patients. Ann Transl Med. 2020 Mar;8(6):308.
   PubMed Web of Science ®Google Scholar
• Qi Nan W, Ling Z, Bing C. The influence of the telomere-telomerase system on diabetes mellitus and its vascular complications. Expert Opin Ther Targets. 2015 Jun;19(6):849–864.
   PubMed Web of Science ®Google Scholar
• Navarro G, Abdolazimi Y, Zhao Z, et al. Genetic disruption of adenosine kinase in mouse pancreatic β-cells protects against high-fat diet-induced glucose intolerance. Diabetes. 2017 Jul;66(7):1928–1938.
   PubMed Web of Science ®Google Scholar
• Minamino T, Orimo M, Shimizu I, et al. A crucial role for adipose tissue p53 in the regulation of insulin resistance. Nat Med. 2009 Sep;15(9):1082–1087.
   PubMed Web of Science ®Google Scholar
• Ping F, Li ZY, Lv K, et al. Deoxyribonucleic acid telomere length shortening can predict the incidence of non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Diabetes Investig. 2017 Mar;8(2):174–180.
   PubMed Web of Science ®Google Scholar
• Alves-Paiva RM, Kajigaya S, Feng X, et al. Telomerase enzyme deficiency promotes metabolic dysfunction in murine hepatocytes upon dietary stress. Liver Int. 2018 Jan;38(1):144–154.
   PubMed Web of Science ®Google Scholar
• Sahin E, Colla S, Liesa M, et al. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature. 2011 Feb 17;470(7334):359–365.
   PubMed Web of Science ®Google Scholar
• Wieckowska A, Feldstein AE Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Seminars in liver disease. 2008 Nov; 28( 4):386–395.
   Google Scholar
• Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999 Jun;116(6):1413–1419.
   PubMed Web of Science ®Google Scholar
• Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999 Sep;94(9):2467–2474.
   PubMed Web of Science ®Google Scholar
• Bi J, Yang L, Wang T, et al. Irisin improves autophagy of aged hepatocytes via increasing telomerase activity in liver injury. Oxid Med Cell Longev. 2020;2020:6946037.
   PubMed Web of Science ®Google Scholar
• Shi T, Yang X, Zhou H, et al. Activated carbon N-acetylcysteine microcapsule protects against nonalcoholic fatty liver disease in young rats via activating telomerase and inhibiting apoptosis. PloS One. 2018;13(1):e0189856.
   PubMed Web of Science ®Google Scholar
• Ma D, Yu Y, Yu X, et al. The changes of leukocyte telomere length and telomerase activity after sitagliptin intervention in newly diagnosed type 2 diabetes. Diabetes Metab Res Rev. 2015 Mar;31(3):256–261.
   PubMed Web of Science ®Google Scholar
• Révész D, Verhoeven JE, Picard M, et al. Associations between cellular aging markers and metabolic syndrome: findings from the cardia study. J Clin Endocrinol Metab. 2018 Jan 1;103(1):148–157.
   PubMed Web of Science ®Google Scholar
• Rode L, Nordestgaard BG, Weischer M, et al. Increased body mass index, elevated C-reactive protein, and short telomere length. J Clin Endocrinol Metab. 2014 Sep;99(9):E1671–5.
   PubMed Web of Science ®Google Scholar
• Aravinthan A, Scarpini C, Tachtatzis P, et al. Hepatocyte senescence predicts progression in non-alcohol-related fatty liver disease. J Hepatol. 2013 Mar;58(3):549–556.
   PubMed Web of Science ®Google Scholar
• Amisaki M, Tsuchiya H, Sakabe T, et al. Identification of genes involved in the regulation of TERT in hepatocellular carcinoma. Cancer Sci. 2019 Feb;110(2):550–560.
   PubMed Web of Science ®Google Scholar
• Laish I, Mannasse-Green B, Hadary R, et al. Telomere dysfunction in nonalcoholic fatty liver disease and cryptogenic cirrhosis. Cytogenet Genome Res. 2016;150(2):93–99.
   PubMed Web of Science ®Google Scholar